Francesco Pignatti

Francesco Pignatti

UNVERIFIED PROFILE

Are you Francesco Pignatti?   Register this Author

Register author
Francesco Pignatti

Francesco Pignatti

Publications by authors named "Francesco Pignatti"

Are you Francesco Pignatti?   Register this Author

49Publications

1048Reads

24Profile Views

Quantifying Preferences in Drug Benefit-Risk Decisions.

Clin Pharmacol Ther 2019 Nov 24;106(5):955-959. Epub 2019 Apr 24.

Department of Management, London School of Economics and Political Science, London, UK.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cpt.1447
Publisher Site
http://dx.doi.org/10.1002/cpt.1447DOI Listing
November 2019

From Individual to Population Preferences: Comparison of Discrete Choice and Dirichlet Models for Treatment Benefit-Risk Tradeoffs.

Med Decis Making 2019 Sep 9:272989X19873630. Epub 2019 Sep 9.

Department of Epidemiology, University of Groningen, University Medical Center Groningen, the Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0272989X19873630DOI Listing
September 2019

Regulatory and Evidence Requirements and the Changing Landscape in Regulation for Marketing Authorisation.

Recent Results Cancer Res 2019;213:169-187

European Medicines Agency, 30 Churchill Place, Canary Wharf, London, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-030-01207-6_11
Publisher Site
http://dx.doi.org/10.1007/978-3-030-01207-6_11DOI Listing
May 2019

Assessment of medical devices: the Emperor's new clothes: Author reply.

Br J Radiol 2018 06 11;91(1086):20180310. Epub 2018 May 11.

7 European Medicines Agency , London , UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20180310DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223301PMC
June 2018

The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.

Oncologist 2015 Mar 11;20(3):329-34. Epub 2015 Feb 11.

European Medicines Agency, London, United Kingdom; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden; Hôpital Saint Louis, Paris, France; North Estonia Regional Hospital, Tallinn, Estonia.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/content/20/3/329.full
Web Search
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4350811PMC
March 2015

The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.

Oncologist 2015 Feb 23;20(2):196-201. Epub 2015 Jan 23.

European Medicines Agency, London, United Kingdom; Statens Legemiddelverk, Norwegian Medicines Agency, Oslo, Norway; Lægemiddelstyrelsen, Danish Health and Medicines Authority, København, Denmark; Läkemedelsverket, Medicinal Products Agency, Uppsala, Sweden; Universitair Ziekenhuis, Ghent, Belgium; European Organization for Research and Treatment of Cancer (EORTC), Brussels, Belgium; Centrum für Operative Urologie Bremen, Bremen, Germany; Karolinska Institute and Hospital, Stockholm, Sweden.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2014-0177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319625PMC
February 2015

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use.

Oncologist 2014 Jul 13;19(7):766-73. Epub 2014 Jun 13.

European Medicines Agency, London, United Kingdom; Danish Health and Medicines Authority, København, Denmark; Department of Physiology and Pharmacology, Università di Roma "La Sapienza," Rome, Italy; Agenzia Italiana del Farmaco, Rome, Italy; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden; Karolinska Institutet, Stockholm, Sweden; The Netherlands Cancer Institute, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0348DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077440PMC
July 2014

The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.

Oncologist 2014 Apr 25;19(4):421-5. Epub 2014 Mar 25.

European Medicines Agency, London, United Kingdom; Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany; Agencia Española de Medicamentos y Productos Sanitarios, Servicio de Farmacología Clínica, Hospital Puerta de Hierro, Madrid, Spain; Läkemedelsverket, Medical Products Agency, Uppsala, Sweden; Hôpital Saint Louis, Paris, France; North Estonia Regional Hospital, Tallinn, Estonia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2013-0294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983815PMC
April 2014

Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.

Clin Cancer Res 2014 Mar;20(6):1458-68

Authors' Affiliations: The European Medicines Agency; Medicines and Healthcare Products Regulatory Agency, London, United Kingdom; Medical Products Agency, Uppsala, Sweden; Paul-Ehrlich-Institut, Langen, Germany; and Medical University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1571DOI Listing
March 2014

Access to patient-level trial data--a boon to drug developers.

N Engl J Med 2013 Oct 21;369(17):1577-9. Epub 2013 Oct 21.

From the European Medicines Agency, London.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1310771DOI Listing
October 2013

Platelet response as the basis for approval in chronic immune (idiopathic) thrombocytopenic purpura (ITP): a regulatory perspective.

Am J Hematol 2012 Oct 17;87(10):943-4. Epub 2012 Sep 17.

European Medicines Agency, London, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23300DOI Listing
October 2012

Regulators, payers, and prescribers: can we fill the gaps?

Lancet Oncol 2011 Sep;12(10):930-1

European Medicines Agency, London, UK.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045117022
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(11)70229-7DOI Listing
September 2011

Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma.

Nat Rev Drug Discov 2008 Oct 12;7(10):818-26. Epub 2008 Sep 12.

European Medicines Agency, Canary Wharf, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd2664DOI Listing
October 2008

Overview of the European regulatory approval system.

J Ambul Care Manage 2004 Apr-Jun;27(2):89-97

European Agency for the Evaluation of Medicinal Products (EMEA), Canary Wharf, London, United Kingdom.

View Article

Download full-text PDF

Source
April 2004

The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.

Eur J Clin Pharmacol 2002 Dec 13;58(9):573-80. Epub 2002 Nov 13.

Safety and Efficacy, Oncology, European Agency for the Evaluation of Medicinal Products, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00228-002-0532-8
Publisher Site
http://dx.doi.org/10.1007/s00228-002-0532-8DOI Listing
December 2002

Clinical trials for registration in the European Union: the EMEA 5-year experience in oncology.

Crit Rev Oncol Hematol 2002 May;42(2):123-35

The European Agency for the Evaluation of Medicinal Products, 7 Westferry Circus, Canary Wharf, London E14 4HB, UK.

View Article

Download full-text PDF

Source
May 2002